Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4

Doss, Wahid; Shiha, Gamal; Hassany, Mohamed; Soliman, Reham; Fouad, Rabab; Khairy, Mohamed M.; Samir, W.; Hammad, Radi; Kersey, Kathryn; Jiang, Deyuan; Doehle, Brian P.; Knox, Steven J.; Massetto, Benedetta; McHutchison, John G.; Esmat, Gamal

doi:10.1016/j.jhep.2015.04.023

Cited by 135 publications

(121 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Undergoing 24 vs. 12 weeks of treatment appears to have some benefit, especially for patients who have cirrhosis. The results in this study are consistent with other studies evaluating treatment with SOF plus RBV for 12 or 24 weeks in Egyptian patients with genotype 4 HCV infection [11,12]. In Ruane et al study on patients of Egyptian origin [11], SVR12 rates were 68% (21/31) following 12 weeks of treatment and 93% (27/29) following 24 weeks of treatment.…”

Section: Discussionsupporting

confidence: 91%

“…Although only a small number of patients had cirrhosis, 43% (3/7)receiving 12 weeks of treatment and 100% (7/7) receiving 24 weeks achieved SVR12. In Doss et al study [12] in Egyptian patients, SVR12 rates were 90% (46/51) with 24 weeks and 77% (40/52) with 12 weeks of SOF and RBV therapy. Patients with cirrhosis at baseline had lower rates of SVR12 (63% for 12 weeks, 78% for 24 weeks) than those without cirrhosis (80% for 12 weeks, 93% for 24 weeks).…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience

Shiha

El-Basiouny

Soliman³

et al. 2016

Medical Journal of Viral Hepatitis

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 92%

Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience

Shiha

El-Basiouny

Soliman³

et al. 2016

Medical Journal of Viral Hepatitis

View full text Add to dashboard Cite

“…SVR12 was achieved in 68% of patients in the 12-week group and in 93% of patients in the 24-week group. Doss et al 39 have also reported their results in 103 treatment-naive or -experienced HCV GT 4 Egyptian patients. SVR12 rates were 90% (46/51) with 24 weeks and 77% (40/52) with 12 weeks of SOF and RBV therapy.…”

Section: Genotypes 4 5 Andmentioning

confidence: 94%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

“…The vast majority of those infected Patients with HCV have not received treatment [9]. Currently Egypt has the greatest burden of advanced liver disease from HCV worldwide, the estimates suggest that in Egypt in 2013, there were 770,000 persons with cirrhosis, 16,000 HCV-related HCC cases and 33,000 HCV-related to liver deaths [10]. Patients with hepatitis B and hepatitis C virus infections are at high risk for development of hepatic fibrosis that may eventually develop cirrhosis and hepatocellular carcinoma [11].…”

Section: Introductionmentioning

confidence: 99%

Comparison between Fibroscan and Serum Taurine for Early Diagnosis of Liver Fibrosis in Egyptian Patients Infected with HCV

Agouza¹,

Fouad²,

Ahmed³

et al. 2017

Clin Med Biochemistry

Self Cite

View full text Add to dashboard Cite

Aim: The aim is to evaluate the role of measuring serum taurine level as an early biomarker for detection and staging of hepatic fibrosis in comparison to Fibroscan. Patients and methods:70 patients who are positive HCV are classified into five groups according to the scoring of Fibroscan. 10 healthy subjects were also enrolled as control group. Full clinical examination and complete biochemical analysis in addition to fibroscan and serum taurine as new marker are performed for all the selected patients and volunteers. Results:Results showed non-significant changes in the most Analytical data between the five groups of patients and control group, but a significant Increment in the serum level of ALT and AST in F4 Stage is noticed and marked decrease in platelets also found in F4. The most interesting point recorded is that Serum taurine levels were exhibited a value markedly lower than that recorded in control group and its decline was related to the severity of the diseases. Conclusion:It is suggested that the assessment of taurine level in sera of all hepatic patients beside fibroscan are of great value in the early diagnosis of any fibrotic changes in liver.

show abstract

Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4

Cited by 135 publications

References 17 publications

Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience

Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Comparison between Fibroscan and Serum Taurine for Early Diagnosis of Liver Fibrosis in Egyptian Patients Infected with HCV

Contact Info

Product

Resources

About